###### Strengths and limitations of this study

-   A critical review of the methodology of the studies and the carotid intima-media thickness measurement methods will be included.

-   Most evidence for this systematic review is expected to derive from observational studies, thus limiting our ability to assess causal relationships, yet facilitating the generalisability of findings across different populations and settings.

-   The review methods were carefully planned according to current guidelines and prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) in order to minimise risk of bias related to study design and conduct, or reporting of results in the completed review.

Introduction {#s1}
============

Rationale {#s1a}
---------

Ultrasound carotid intima-media thickness (CIMT) is a non-invasive technique that is used in adult and paediatric populations for the assessment of subclinical cardiovascular disease (CVD) and as a surrogate end point for treatment efficacy in research settings.[@R1] Ultrasound CIMT correlates well with its histological measurement[@R5] and coronary atherosclerosis.[@R6] It has been argued, however, that elevated CIMT is not always equivalent to subclinical atherosclerosis. At lower degrees of thickness and at early ages, it may represent hypertrophy of the intimal and medial layers in the absence of true atherosclerotic lesions.[@R7] Nevertheless, increased CIMT as an adaptive response to blood flow, intraluminal pressure or other biological factors relates to the known pathophysiology of atherosclerosis.[@R9]

In adults, CIMT is associated with traditional CVD risk factors[@R11] and is predictive of heart attack and stroke.[@R1] Longitudinal studies showed that elevated CIMT in adulthood is linked to risk factors in childhood,[@R18] such as obesity, high serum cholesterol and insulin levels.[@R19] In children, several studies assessed CIMT and its relation with risk factors such as obesity,[@R22] dyslipidaemia,[@R3] elevated blood pressure[@R25] or smoking.[@R27] CIMT was also used to assess CVD risk in paediatric patients with clinical conditions that are associated with accelerated atherosclerosis, for instance, diabetes or chronic kidney disease.[@R28] Clinical trials in children and adolescents showed a decrease in CIMT following interventions to control risk factors.[@R35] Furthermore, there is growing evidence that prenatal factors are also determinants of cardiovascular health across the life course and may have an effect on CIMT.[@R37] These data provide support for CIMT as a marker of vascular remodelling in youth. However, it remains to be determined among which children CIMT is increased and if it is clinically relevant to measure it.[@R39] Further, a comprehensive overview, in a life-course epidemiology perspective,[@R40] of the prenatal and postnatal factors associated with CIMT in children is lacking.

The heterogeneity in CIMT measurement methods requires careful consideration as several methodological aspects related to the site of measurement, the edge detection approach and ultrasound settings, or the training level of the operators influence the quality and interpretation of results.[@R9] Standardised equipment and imaging protocols, as well as sonographers' high expertise, are essential for CIMT acquisition and analysis.[@R42] Also, the technique can be challenging, especially in young children, depending on the patient's compliance and anatomic particularities.[@R39] Still, our research group proved that CIMT assessment is feasible and reproducible in non-sedated infants.[@R45] Due to differences in CIMT measurement technique, the between-study comparability is commonly considered to be limited. Nevertheless, a formal evaluation of the CIMT measurement methods in children is needed for further clarification of this limitation.

Objectives {#s1b}
----------

Therefore, our objective is to systematically review the evidence on the relationship between CIMT and prenatal and postnatal exposures or interventions in children from birth up to 18 years, as well as documenting and discussing the CIMT measurement methods.

Methods and analysis {#s2}
====================

The protocol has been developed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements,[@R46] the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines[@R49] and following methods outlined in the *Cochrane Handbook for Systematic Reviews of Interventions*.[@R50] This systematic review has been registered with the International Prospective Register of Systematic Reviews (registration number CRD42017075169).

Eligibility criteria {#s2a}
--------------------

### Study designs {#s2a1}

Observational and experimental primary research studies will be eligible. The following study designs will be considered: cohort, case--control and cross-sectional studies; randomised and non-randomised, controlled and non-controlled trials; quasi-experimental studies. Case reports, case series, opinion papers, letters to the editor, comments, conference proceedings, policy papers, reviews and meta-analyses, study protocols without baseline data and animal studies will be excluded.

### Participants {#s2a2}

We will include studies in children from birth up to 18 years. Studies with both children and adults will be included if the data for children can be extracted separately. Both apparently healthy children and subjects with clinical conditions will be included.

### Exposures/interventions {#s2a3}

There will be no restrictions regarding the types of exposures or interventions considered in the primary studies. Prenatal and postnatal exposures, at the individual or environmental level, will be considered for inclusion. Examples might include gestational age, birth weight, maternal gestational diabetes, traditional CVD risk factors (blood pressure, blood lipids, etc), specific at-risk clinical conditions (chronic kidney disease, diabetes mellitus, familial hypercholesterolemia, HIV infection, chronic inflammatory disease, etc) or tobacco exposure. For experimental studies, we will consider both pharmacological and non-pharmacological interventions (eg, interventions to promote physical activity or smoking cessation, treatments with antihypertensive or lipid-lowering drugs).

### Comparators {#s2a4}

Studies assessing specific clinical conditions in relationship with CIMT will be included provided they use a control group without the clinical condition of interest.

### Outcome measures {#s2a5}

The outcome will be the intima-media thickness of the carotid artery measured by ultrasonography.

### Time frame {#s2a6}

There will be no restriction by duration of intervention or by length of follow-up.

### Setting {#s2a7}

There will be no restriction by type of setting.

### Language {#s2a8}

Studies in English and French will be included.

Search strategy {#s2b}
---------------

Systematic searches will be conducted in the following databases: (1) Medical Literature Analysis and Retrieval System Online (MEDLINE) from 1946 onwards (PubMed interface); (2) Excerpta Medica database (EMBASE) from 1947 to present (via <http://embase.com>); and (3) Cochrane Central Register of Controlled Trials (CENTRAL) from 1947 onwards (Wiley interface). The search strategy structures for these databases were reviewed and refined by two experienced librarians. They were constructed to include the two main concepts of this systematic review: (1) children and adolescents and (2) CIMT. The search strategy for MEDLINE ([Box 1](#BX2){ref-type="boxed-text"}) was created first and then adapted for the other two databases ([supplementary appendix 1 and 2](#SP1){ref-type="supplementary-material"} in the online supplementary material file). The reference lists of the retrieved articles and other reviews in the field will be browsed to identify further studies of interest. Supplementary searches will be conducted on Web of Science and Google Scholar. To identify unpublished or ongoing studies, we will search the following registers: the ClinicalTrials.gov (<http://www.clinicaltrials.gov>), the EU Clinical Trials Register (<http://www.clinicaltrialsregister.eu>) and the International Clinical Trials Registry Platform (<http://www.isrctn.com>). The principal investigators of completed studies found on these trial registers will be contacted, via email, to access unpublished data.Box 1Search strategy for Medical Literature Analysis and Retrieval System Online (MEDLINE)baby\[tiab\] OR babies\[tiab\] OR preterm\*\[tiab\] OR pre-term\*\[tiab\] OR prematur\*\[tiab\] OR newborn\*\[tiab\] OR infan\*\[tiab\] OR infant\[mh\] OR toddler\*\[tiab\] OR kindergart\*\[tiab\] OR kid\[tiab\] OR kids\[tiab\] OR boy\*\[tiab\] OR girl\*\[tiab\] OR preschool\*\[tiab\] OR pre-school\*\[tiab\] OR child\*\[tiab\] OR child\[mh\] OR school\*\[tiab\] OR preteen\*\[tiab\] OR prepube\*\[tiab\] OR preadolescen\*\[tiab\] OR highschool\*\[tiab\] OR high-school\*\[tiab\] OR student\*\[tiab\] OR adolescen\*\[tiab\] OR adolescent\[mh\] OR teen\*\[tiab\] OR pube\*\[tiab\] OR youngster\*\[tiab\] OR youth\*\[tiab\] OR pediatric\*\[tiab\] OR paediatric\*\[tiab\] OR peadiatric\*\[tiab\] OR pediatrics\[mh\] OR neonat\*\[tiab\] OR perinat\*\[tiab\] OR offspring\[tiab\] OR descendant\*\[tiab\]"intima media thickness"\[tiab\] OR "intima media thickening"\[tiab\] OR "intimal medial thickness"\[tiab\] OR "intimal medial thickening"\[tiab\] OR "intimal media thickness"\[tiab\] OR "intimal media thickening"\[tiab\] OR "intima medial thickness"\[tiab\] OR "intima medial thickening"\[tiab\] OR "intima media complex"\[tiab\] OR "intimal medial complex"\[tiab\] OR "intimal media complex"\[tiab\] OR "intimamedia thickness"\[tiab\] OR "wall thickness"\[tiab\] OR "wall thickening"\[tiab\] OR "arterial thickness"\[tiab\] OR "artery thickness"\[tiab\] OR "artery wall thickness"\[tiab\] OR "arterial wall thickness"\[tiab\] OR "intimal thickening"\[tiab\] OR "tunica intima/diagnostic imaging"\[mh\] OR "tunica media/diagnostic imaging"\[mh\]carotid\[tiab\] OR "arteria carotis"\[tiab\] OR "carotid arteries"\[mh\] OR "carotid artery diseases"\[mh:noexp\]atherosclero\*\[tiab\] OR atherosclerosis\[mh\] OR arteriosclero\*\[tiab\] OR arteriosclerosis\[mh\] OR "end organ damage"\[tiab\] OR "target organ damage"\[tiab\] OR "cardiovascular diseases"\[mh:noexp\]ultrasound\[tiab\] OR echograph\*\[tiab\] OR ultrasonograph\*\[tiab\] OR sonograph\*\[tiab\] OR ultrasonography\[mh\]\#2 AND \#3\#3 AND \#4 AND \#5"carotid intima-media thickness"\[mh\] OR "carotid arteries/diagnostic imaging"\[mh\]\#6 OR \#7 OR \#8\#1 AND \#9\#10 NOT (animals\[mh\] NOT humans\[mh\])[^1]
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Study selection {#s2c}
---------------

An initial evaluation of the collection of articles will be performed to eliminate duplicate publications. Studies will be assessed for inclusion against prespecified criteria independently and in parallel by two reviewers (AME and ML). This process will be conducted in two stages, initially on the basis of titles and abstracts and then by reviewing the full text of the articles retained in the first step. Any disagreements between the two reviewers will be solved by discussion. If consensus is not reached, arbitration by a third reviewer (AC) will be required. The decisions made for each article will be recorded. The systematic reviews software Covidence (Veritas Health Innovation, Melbourne, Australia; <http://www.covidence.org>) will be used to manage the study selection process.

Data extraction {#s2d}
---------------

Data will be extracted independently by two reviewers (AME and ML) using an electronic database created in Microsoft Office Excel 2007. Disagreements will be resolved by discussion or, if necessary, with the arbitration of a third reviewer (AC). Drop-down lists will be created whenever appropriate to minimise errors. Calibration exercises will be conducted before this review stage to enhance consistency between assessors. Two members of the review team (ML and AC) have previous experience in study quality appraisal and data collection for systematic reviews.[@R51]

The following data items will be extracted:Study identification: authors, publication year, journal, funding or sponsorship.Study characteristics: study type (observational or experimental), study design, country, sampling procedure, sample size, study setting, study duration or period of follow-up, participation rates.Study subjects characteristics: inclusion and exclusion criteria, age, sex, ethnicity, anthropometric measures; we will also extract data on medication/co-interventions and comorbidities in children with clinical conditions.Exposures or interventions:Exposure type and its characteristics (definition and cut-offs, measurement method, follow-up period/duration of exposure).Intervention type and its characteristics (dosage/intensity, frequency, duration, personnel who deliver it, etc).Outcome:CIMT definition and additional features of the CIMT measurement method ([Box 2](#BX3){ref-type="boxed-text"}), number of measurements.Potential confounding and effect modifiers:Confounding factors and effect modifiers considered in the primary studies, depending on the exposure or intervention of interest, will be documented and taken into account when performing data analysis (eg, gestational age, birth weight, blood pressure, blood lipids, blood glucose, tobacco exposure, family history of CVD, physical activity or sedentary behaviour).Adjusted and unadjusted measures of effect or association will be recorded. Box 2Carotid intima-media thickness (CIMT) characteristicsEquipmentUltrasound device typeUltrasound settings: imaging technique (eg, B-mode, M-mode), transducer (array, frequency)Cardiac cycle tracking method (eg, electrocardiography, other)Data storage facilitiesImage acquisition and analysisSide (right, left, combination), segment (common carotid artery, internal carotid artery, carotid bifurcation, combination), wall (far-wall, near-wall, combination), angle of insonationAtherosclerotic plaque (inclusion or exclusion of plaque, definition of plaque)Type of measurement (eg, manual, semiautomatic or automatic)Timing during the cardiac cycle (eg, irrespective of the cardiac cycle, end-diastole, other)Segmental calculation (ie, mean or maximum CIMT)Quality control proceduresUse of a predefined standardised imaging protocol, training level of operators, type and number of operators (sonographers, readers)Assessment of reproducibility of measurements (ie, intraoperator and/or interoperator variability indices)Any other quality control measures taken (eg, phantom scans, maintenance routine of the equipment)

We will collate information provided in multiple reports of the same study if they aim to assess the same exposure/intervention. If their aim is to assess different exposures/interventions, multiple reports of the same study will be considered separately in this systematic review. When CIMT measurements are available at several time points, the time point closest to the end of the intervention or the follow-up period will be selected for data extraction. When essential information is missing from the published reports, we will contact the authors of the original studies by email to access missing data. A maximum of three email attempts per study will be undertaken.

Study quality {#s2e}
-------------

Quality appraisal will be performed independently by two reviewers (AME and ML). Any disagreements will be solved by discussion or, if necessary, with the arbitration of a third reviewer (AC). Quality assessment of experimental studies will be conducted in line with the Cochrane collaboration's risk of bias tool.[@R50] Observational studies will be evaluated using the Newcastle-Ottawa Scale for non-randomised studies.[@R55]

The reliability of the CIMT measurement methods used in primary studies will be evaluated following a predefined tool developed for the current review based on existing standards,[@R9] and with input from the review team members with expertise in CIMT measurement (YM, SDB, NS). The following three domains will be appraised: (1) site of measurement, (2) image analysis methods and (3) assessment of reproducibility. The complete tool and the algorithm of judgement are presented in the online [supplementary appendix 3](#SP1){ref-type="supplementary-material"}.

Data analysis {#s2f}
-------------

The following software programs will be used to carry out statistical analyses: RStudio (V.0.99.473), Stata (V.14.1) and RevMan (V.5.3) (Copenhagen: The Nordic Cochrane Centre, 2014).

### Measures of effect or association {#s2f1}

For experimental studies, the measure of effect for continuous outcomes will be the difference in means between the intervention and the control groups. For categorical outcomes, the measure of effect will be the OR or the relative risk. For observational studies, the measure of association for continuous outcomes will be the correlation or regression coefficient, or the difference in means between the exposure and the control groups. For categorical outcomes, the measure of association will be the OR at different exposure levels.

### Descriptive analyses {#s2f2}

The characteristics of the study population and details about the CIMT measurement methods reported in each study will be presented in text and tables. We will also perform a descriptive analysis of studies: (1) not providing sufficient data to be included in the meta-analyses and (2) reporting results in a format that cannot be converted to a standard metric and/or common effect size measure.

### Meta-analyses {#s2f3}

If possible, we will pool results across studies for each type of exposure or intervention. This will be conducted separately for observational and experimental studies. Meta-analyses will be computed using random-effects models as heterogeneity is expected.[@R58] Results will be presented graphically through forest plots. If studies are not sufficiently homogenous to be combined in a quantitative synthesis, their results will be presented in a narrative format or in graphical displays having the pooled estimate suppressed.[@R50] The comparability of studies will be judged based on the CIMT definition and the clinical characteristics of the studied population.

### Assessment of heterogeneity {#s2f4}

Statistical heterogeneity will be evaluated using the Cochran's Q test and will be quantified using the I^2^ method.[@R50] If sufficient studies are available, the sources of variability will be investigated by means of subgroup analyses accompanied by interaction tests and meta-regression based on the following variables:Study design, study setting, duration of intervention or duration of exposure/follow-up.Sample characteristics: sample size, age, sex.Properties of the CIMT measurement method: far-wall versus near-wall or combination of walls, one side versus both sides, manual versus semiautomatic/automatic measurements, transducer frequency.

Sensitivity analyses will be carried out by (1) excluding relatively small studies, (2) excluding studies of low quality and (3) restricting analyses to studies having the end point defined as mean CIMT.

### Assessment of publication bias {#s2f5}

Publication bias will be assessed by visual inspection of funnel plots, and, if sufficient studies will be available, funnel plot asymmetry will be examined using the Egger's test.[@R50]

### Assessment of strength of evidence {#s2f6}

The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework will be applied in order to assess the strength of the body of evidence for this systematic review.[@R60]

Patient and public involvement {#s2g}
------------------------------

This is a protocol for a systematic review and there was no patient or public involvement in framing the research objective or study design.
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======================
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